Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Appends its LGND Research Report - WTVM.com-Columbus, GA News Weather & Sports

Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Appends its LGND Research Report

  • HEALTHMore>>

  • News 9 MD: New strides in leg lengthening technology

    News 9 MD: New strides in leg lengthening technology

    Friday, September 12 2014 6:13 AM EDT2014-09-12 10:13:07 GMT
    Imagine if one of your legs was longer than the other. It might not sound like a serious problem, but it could lead to severe hip or back pain if not treated. Now, there's a new way to permanently lengthenMore >>
    Imagine if one of your legs was longer than the other. It might not sound like a serious problem, but it could lead to severe hip or back pain if not treated. Now, there's a new way to permanently lengthenMore >>
  • News 9 MD: Heart surgery and transfusions

    News 9 MD: Heart surgery and transfusions

    Friday, September 5 2014 6:20 AM EDT2014-09-05 10:20:12 GMT
    One-fifth of the nation's entire blood supply used during heart surgery and blood transfusions is not only costly, but they can pose risks for patients. Some hospitals in the U.S. are significantly reduciMore >>
    Every two seconds in the United States, someone needs blood. One-fifth of the nation's entire blood supply used during heart surgery and blood transfusions is not only costly, but they can pose risks for patients. Some hospitals in the U.S. are significantly reducing transfusion rates during heart surgery.More >>
  • News 9 MD: Ear cancer survivor gets new "ear"

    News 9 MD: Ear cancer survivor gets new "ear"

    Friday, August 29 2014 6:38 AM EDT2014-08-29 10:38:07 GMT
    Whether he's playing hockey or flying high, Henry Fiorentini lives an active lifestyle. But a few years ago, a very common form of skin cancer called basal cell carcinoma almost took his life. "It'sMore >>
    Whether he's playing hockey or flying high, Henry Fiorentini lives an active lifestyle. But a few years ago, a very common form of skin cancer called basal cell carcinoma almost took his life. "It'sMore >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Lemelson Capital Management, LLC

MARLBOROUGH, Mass., July 7, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND) and appended with additional concerns its initial June 16, 2014 research report. 

Today's appended report can be found here

"The ancillary applications for Ligand's Promacta® and Kyprolis® have no commercial viability, and the company's Duavee® sales remain immaterial," Lemelson Capital Management's Chief Investment Officer Emmanuel Lemelson said in releasing today's appended Ligand Pharmaceuticals report.  "There is no circumstance where speculation has a legitimate value greater than zero," he said.

Today's appended research report on Ligand Pharmaceuticals includes new material information that has been added to the firm's original June 16, 2014 research report, which can be found here.

Disclosure: Lemelson Capital is currently short shares of LGND for its clients.

About Lemelson Capital Management:

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments.  The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds.  For more information, see:  http://www.lemelsoncapital.com

Contact:

+Emmanuel Lemelson, Chief Investment Officer, Lemelson Capital Management, LLC
(508) 630-2281

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

1909 Wynnton Road
Columbus, Ga. 31906

FCC Public File
publicfile@wtvm.com
706-494-5400
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WTVM. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.